Navigation Links
DRAXIS Share Buyback Approved by TSX
Date:1/16/2008

s only as of the date made.

These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors that could cause the Company's results or performance to differ materially from a conclusion, forecast or projection in the forward-looking statements include, but are not limited to:

- the achievement of desired clinical trial results related to the

Company's pipeline products;

- timely regulatory approval of the Company's products;

- the ability to comply with regulatory requirements applicable to the

manufacture and marketing of the Company's products;

- the Company's ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

the Company and its products;

- factors beyond our control that could cause interruptions in our

operations in our single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- the Company's dependence on a small number of key customers;

- the disclosure of confidential information by our collaborators,

employees or consultants;

- the preservation of healthy working relationships with the Company's

union and employees;

- the Company's ability to grow the business;

- the fluctuation of our financial results and exchange and interest

rate fluctuations;

- the adaptation to changing technologies;

- the loss of ke
'/>"/>

SOURCE DRAXIS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. DRAXIS Announces Application for Normal Course Issuer Bid
2. DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
3. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
4. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
5. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
6. Regence Enables Members to Share Feedback With Each Other When Researching Health Care Provider Options
7. AlphaRx CEO Accumulates More Company Shares
8. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
9. HearAtLast Holdings, Inc. Provides Shareholder Update
10. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
11. Body Abnormalities, Childhood Cancer May Share Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, and ... and regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t Just Age” will ... thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort ... 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and other management and ...
(Date:7/31/2015)... ... ... The Mount Sinai Health System will work with Columbia Care LLC, a ... treatments. The collaboration moves into the next phase with the recent decision by the ... licenses to produce and dispense medical marijuana. , Mount Sinai and Columbia Care ...
(Date:7/31/2015)... ... 2015 , ... Like nearly every other form of surgery, it shouldn't come ... effective and less intrusive and painful. Leading these advances in the United States ... currently stands as the only doctor in the United States who is qualified to ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2
... Better understanding of genetic, biological causes could lead more ... (HealthDay News) -- When people understand the genetics and ... blame those with the eating disorder for their illness, ... (UNC) study. , "This is a potentially important ...
... of women showed effect lasted long after program ended ... exercises can help relieve chronic neck pain, says a ... Care & Research . , Previous studies have produced ... pain, but there hasn,t been enough high-quality research to ...
... immune system should fight tumors, researchers say , , ... to fight ovarian and breast cancer are in ... their safety and effectiveness, researchers report. , The ... Coukos, an assistant professor at the University of ...
... The state,s most highly-respected minds in medicine and emergency ... to improve Missouri,s emergency response systems, JEFFERSON CITY, ... will meet Tuesday, January 15, 2008, to compile,recommendations for ... the mortality and morbidity associated with stroke and ST-Segment,Elevation ...
... With a continued focus on,quality and ... to focus on opportunities for streamlining processes ... functions for,manufacturing organizations, the majority of the ... centralization could provide several,worthwhile benefits, as found ...
... for Collective Bargaining, ,Prompt Pay,Legislation, WASHINGTON, Jan. ... of Inspector General (OIG) on independent pharmacy payments ... Hill and runs counter to,claims from the independent ... today., "This report will raise eyebrows among ...
Cached Medicine News:Health News:Science Could Erase Stigma of Anorexia 2Health News:Strength Training Eases Chronic Neck Pain 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 3Health News:Time Critical Diagnosis Task Force Convenes in Jefferson City 2Health News:Manufacturing Organizations Identify Efficiencies in Maintenance Functions 2Health News:PCMA: New Study on Independent Pharmacy Reimbursements Will 'Raise Eyebrows' on Capitol Hill 2
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... A Commonwealth Fund case study notes that ... aligned "to launch innovations and organize services in ways that make ... study -- along other profiles looking at medical systems that have ... high performing health care system -- has been in the works ...
... Conatus Pharmaceuticals Inc. announced today the initiation of a ... for the treatment of liver disease associated with Hepatitis C ... treatment with approved standard of care treatments is not currently ... patients who failed standard of care treatment are expected to ...
Cached Medicine Technology:Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: